The shadow of generic rivalry has consistently loomed over copyright’s famous drug, Sildenafil, triggering questions about the future of connected pharmaceutical holdings. While early years saw impressive gains, the patent lapse has created the path for cheaper substitutes, likely diminishing profitability and presenting a genuine danger for inve